BR9907866A - Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia - Google Patents

Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia

Info

Publication number
BR9907866A
BR9907866A BR9907866-0A BR9907866A BR9907866A BR 9907866 A BR9907866 A BR 9907866A BR 9907866 A BR9907866 A BR 9907866A BR 9907866 A BR9907866 A BR 9907866A
Authority
BR
Brazil
Prior art keywords
combination
fibrate
metformin
pharmaceutical composition
preparation
Prior art date
Application number
BR9907866-0A
Other languages
English (en)
Other versions
BRPI9907866B8 (pt
BRPI9907866B1 (pt
Inventor
Yves Bonhomme
Philippe Briet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9907866A publication Critical patent/BR9907866A/pt
Publication of BRPI9907866B1 publication Critical patent/BRPI9907866B1/pt
Publication of BRPI9907866B8 publication Critical patent/BRPI9907866B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção:<B>''COMPOSIçãO FARMACêUTICA COMPREENDENDO UMA COMBINAçãO DE METFORMINA E FIBRATO, E SEU USO PARA A PREPARAçãO DE MEDICINAS DESTINADAS A REDUZIR A HIPERGLICEMIA"<D>. A presente invenção refere-se a uma composição farmacêutica compreendendo, como princípios ativos, (i) metformina opcionalmente na forma de um de seus sais farmaceuticamente aceitáveis, e (ii) um fibrato escolhido de fenofibrato e bezafibrato, em combinação com um ou mais excipientes farmaceuticamente aceitáveis. Estas composições são particularmente adequadas para o tratamento de diabetes não dependente de insulina.
BR9907866A 1998-02-12 1999-01-30 composição farmacêutica, bem como seu uso BRPI9907866B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FR9801709 1998-02-12
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (3)

Publication Number Publication Date
BR9907866A true BR9907866A (pt) 2000-10-31
BRPI9907866B1 BRPI9907866B1 (pt) 2017-08-15
BRPI9907866B8 BRPI9907866B8 (pt) 2021-05-25

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907866A BRPI9907866B8 (pt) 1998-02-12 1999-01-30 composição farmacêutica, bem como seu uso

Country Status (27)

Country Link
US (1) US6372790B1 (pt)
EP (1) EP1054665B1 (pt)
JP (1) JP4767411B2 (pt)
KR (1) KR100567608B1 (pt)
CN (1) CN1151785C (pt)
AR (1) AR018286A1 (pt)
AT (1) ATE204754T1 (pt)
AU (1) AU746821B2 (pt)
BR (1) BRPI9907866B8 (pt)
CA (1) CA2320039C (pt)
CZ (1) CZ290101B6 (pt)
DE (1) DE69900249T2 (pt)
DK (1) DK1054665T3 (pt)
ES (1) ES2162517T3 (pt)
FR (1) FR2774591B1 (pt)
HU (1) HU224619B1 (pt)
ID (1) ID26254A (pt)
MY (1) MY118164A (pt)
NO (1) NO328314B1 (pt)
PL (1) PL196874B1 (pt)
PT (1) PT1054665E (pt)
RU (1) RU2207850C2 (pt)
SK (1) SK283212B6 (pt)
TW (1) TW518222B (pt)
UA (1) UA70315C2 (pt)
WO (1) WO1999040904A2 (pt)
ZA (1) ZA991077B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
ATE411010T1 (de) 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
CN101822834A (zh) * 2003-02-07 2010-09-08 味之素株式会社 糖尿病治疗药
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
AU2006346853A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Drug formulation containing fibrate medicament and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
EP2872483A4 (en) * 2012-07-10 2016-03-16 Thetis Pharmaceuticals Llc THREE METFORMIN SALT FORM
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CA2951923A1 (en) 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
US20250127900A1 (en) * 2021-12-22 2025-04-24 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
FR2264525B1 (pt) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
FR2774591A1 (fr) 1999-08-13
EP1054665B1 (en) 2001-08-29
PL196874B1 (pl) 2008-02-29
SK11562000A3 (sk) 2000-12-11
CA2320039C (en) 2008-07-22
AU2923399A (en) 1999-08-30
SK283212B6 (sk) 2003-03-04
EP1054665A2 (en) 2000-11-29
ID26254A (id) 2000-12-07
KR100567608B1 (ko) 2006-04-04
NO328314B1 (no) 2010-01-25
NO20004056D0 (no) 2000-08-11
CZ290101B6 (cs) 2002-05-15
NO20004056L (no) 2000-08-11
PL342665A1 (en) 2001-07-02
WO1999040904A2 (en) 1999-08-19
HK1034913A1 (en) 2001-11-09
ZA991077B (en) 1999-08-11
WO1999040904A3 (en) 1999-09-30
HU224619B1 (hu) 2005-11-28
RU2207850C2 (ru) 2003-07-10
CN1290160A (zh) 2001-04-04
HUP0100801A3 (en) 2001-12-28
MY118164A (en) 2004-09-30
CA2320039A1 (en) 1999-08-19
TW518222B (en) 2003-01-21
ES2162517T3 (es) 2001-12-16
JP4767411B2 (ja) 2011-09-07
KR20010040925A (ko) 2001-05-15
JP2002502869A (ja) 2002-01-29
DE69900249D1 (de) 2001-10-04
AU746821B2 (en) 2002-05-02
AR018286A1 (es) 2001-11-14
BRPI9907866B8 (pt) 2021-05-25
US6372790B1 (en) 2002-04-16
PT1054665E (pt) 2002-02-28
DE69900249T2 (de) 2002-06-13
FR2774591B1 (fr) 2000-05-05
CN1151785C (zh) 2004-06-02
ATE204754T1 (de) 2001-09-15
UA70315C2 (en) 2004-10-15
HUP0100801A2 (hu) 2001-08-28
BRPI9907866B1 (pt) 2017-08-15
CZ20002828A3 (cs) 2000-11-15
DK1054665T3 (da) 2001-12-27

Similar Documents

Publication Publication Date Title
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
ES2550094T3 (es) Composiciones de N-acetilcisteína y métodos de tratamiento y de prevención de la toxicidad de los medicamentos
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
BR9910928A (pt) Composto, processo para a prepará-lo, uso do mesmo, formulação, e, processo para a profilaxia e/ou tratamento de condições clinicas associadas com resistência a insulina
BR0214403A (pt) Composições farmacêuticas compreendendo metformina e glibenclamida para o tratamento de diabetes melittus tipo ii
RU2000123567A (ru) Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
BG106906A (bg) Пуринови производни
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR012995A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos.
BR0211198A (pt) Composições farmacêuticas e seu uso
BR0016135A (pt) Forma de tamanho de partìcula reduzido, uso de uma substância, composição farmacêutica, métodos para o tratamento ou a profilaxia de condições associadas com reduzida sensibilidade à insulina e de deslipidemia, diabetes melito do tipo ii, hiperglicemia, hiperinsulinemia, hipertensão arterial e/ou obesidade abdominal e processo para a preparação de um composto
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
DE60219963D1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
BRPI9509819B8 (pt) benzamida enterocinética e composição farmacêutica compreendendo a mesma
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
SE0000303D0 (sv) Novel compounds

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/00, A61K 31/195, A61P 3/10

Ipc: A61K 31/00 (2008.04), A61K 31/195 (2008.04), A61P

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART .8O COMBINADO COM ART. 13 E ART. 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/01/2019